Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure

Trial Profile

Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Jun 2021

At a glance

  • Drugs INO 4800 (Primary)
  • Indications COVID 2019 infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms INNOVATE
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 08 Jun 2021 According to an Inovio Pharmaceuticals media release, the companies will evaluate the safety and efficacy of INO-4800 in a two-dose regimen (2.0 mg), administered one month apart, in a two-to-one randomization in subjects 18 years and older across several countries, primarily in Latin America and Asia
    • 10 May 2021 According to an Inovio Pharmaceuticals media release, Company plans to file preliminary Phase 2 results and device data with the U.S. Food and Drug Administration (FDA).
    • 10 May 2021 According to an Inovio Pharmaceuticals media release, result has been published as a pre-print in MedRxiv.

Trial Overview

Purpose

This phase II/III study will evaluate the efficacy, safety, tolerability and immunogenicity of INO-4800 (a Covid-19 DNA vaccine candidate).
The Phase 2 segment of the trial is designed to evaluate safety, tolerability and immunogenicity of INO-4800 in a 2-dose regimen (1.0 mg or 2.0 mg), in a three-to-one randomization to receive either INO-4800 or placebo for each dose, to confirm the more appropriate dose(s) for each of three age groups (18-50 years, 51-64 years and 65 years and older) for the subsequent Phase 3 efficacy evaluation.
In the Phase 3 segment of the trial, INOVIO intends to enroll healthy men and non-pregnant women 18 years and older, to evaluate the efficacy of the proposed dose(s) based on the data from the Phase 2 evaluation. Participants will be enrolled in a one-to-one randomization to receive either INO-4800 or a placebo. The Phase 3 segment will be case-driven with the final number of enrollees to be determined by the incidence of COVID-19 during the Phase 3 segment.

Comments

According to an Inovio Pharmaceuticals media release, Company plans to file preliminary Phase 2 results and device data with the U.S. Food and Drug Administration (FDA).

According to an Inovio Pharmaceuticals media release, given the increasing availability of vaccines authorized for emergency use, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, in coordination with the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency, will discontinue funding for the Phase 3 segment of the trial, while continuing to fund the completion of phase 2 segment.

Primary Endpoints

Phase 2: Change From Baseline in Antigen-specific Cellular Immune Response Measured by Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Assay

time_frame: Baseline up to Day 393

Phase 2: Change From Baseline in Neutralizing Antibody Response Measured by a Pseudovirus-based Neutralization Assay

time_frame: Baseline up to Day 393

Phase 3: Percentage of Participants With Virologically-confirmed COVID-19 Disease

time_frame: From 14 days after completion of the 2-dose regimen up to 12 months post-dose 2 (i.e. Day 42 up to Day 393)

Other Endpoints

Phase 2 and 3: Percentage of Participants With Solicited and Unsolicited Injection Site Reactions

time_frame: From time of consent up to 28 days post-dose 2 (up to Day 56)

Phase 2 and 3: Percentage of Participants With Solicited and Unsolicited Systemic Adverse Events (AEs)

time_frame: From time of consent up to 28 days post-dose 2 (up to Day 56)

Phase 2 and 3: Percentage of Participants With Serious Adverse Events (SAEs)

time_frame: Baseline up to Day 393

Phase 2 and 3: Percentage of Participants With Adverse Events of Special Interest (AESIs)

time_frame: Baseline up to Day 393

Phase 3: Percentage of Participants With Death From All Causes

time_frame: Baseline up to Day 393

Phase 3: Percentage of Participants With Non-Severe COVID-19 Disease

time_frame: From 14 days after completion of the 2-dose regimen up to 12 months post-dose 2 (i.e. Day 42 up to Day 393)

Phase 3: Percentage of Participants With Severe COVID-19 Disease

time_frame: From 14 days after completion of the 2-dose regimen up to 12 months post-dose 2 (i.e. Day 42 up to Day 393)

Phase 3: Percentage of Participants With Death From COVID-19 Disease

time_frame: From 14 days after completion of the 2-dose regimen up to 12 months post-dose 2 (i.e. Day 42 up to Day 393)

Phase 3: Percentage of Participants With Virologically-Confirmed SARS-CoV-2 Infections

time_frame: From 14 days after completion of the 2-dose regimen up to 12 months post-dose 2 (i.e. Day 42 up to Day 393)

Phase 3: Days to Symptom Resolution in Participants With COVID-19 Disease

time_frame: From 14 days after completion of the 2-dose regimen up to 12 months post-dose 2 (i.e. Day 42 up to Day 393)

Phase 3: Change From Baseline in Antigen-specific Cellular Immune Response Measured by IFN-gamma ELISpot Assay

time_frame: Baseline up to Day 393

Phase 3: Change From Baseline in Neutralizing Antibody Response Measured by a Pseudovirus-based Neutralization Assay

time_frame: Baseline up to Day 393 [1]

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention -

Subjects

  • Subject Type patients
  • Number

    Planned: 6578

    Actual: 401

  • Sex male & female
  • Age Group ≥ 18 years; adult

Patient Inclusion Criteria

Key - Working or residing in an environment with high risk of exposure to SARS-CoV-2 for whom exposure may be relatively prolonged or for whom personal protective equipment (PPE) may be inconsistently used, especially in confined settings. - Screening laboratory results within normal limits for testing laboratory or are deemed not clinically significant by the Investigator. - Be post-menopausal or be surgically sterile or have a partner who is sterile or use medically effective contraception with a failure rate of < 1% per year when used consistently and correctly from Screening until 3 months following last dose. Key

Patient Exclusion Criteria

- Acute febrile illness with temperature higher than 100.4°F (38.0°C) or acute onset of upper or lower respiratory tract symptoms (e.g., cough, shortness of breath, sore throat). - Positive serologic or molecular (Reverse transcription polymerase chain reaction (RT-PCR)) test for SARS-CoV-2 at Screening. - Pregnant or breastfeeding or intending to become pregnant or intending to father children within the projected duration of the trial starting from the Screening visit until 3 months following the last dose. - Known history of uncontrolled HIV based on a CD4 count less than 200 cells per cubic millimeter (/mm^3) or a detectable viral load within the past 3 months. - Is currently participating or has participated in a study with an investigational product within 30 days preceding Day 0. - Previous receipt of an investigational vaccine for prevention or treatment of COVID-19, middle east respiratory syndrome (MERS), or severe acute respiratory syndrome (SARS) (documented receipt of placebo in previous trial would be permissible for trial eligibility). - Respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease) requiring significant changes in therapy or hospitalization for worsening disease during the 6 weeks prior to enrolment. - Immunosuppression as a result of underlying illness or treatment. - Lack of acceptable sites available for ID injection and EP. - Blood donation or transfusion within 1 month prior to Day 0. - Reported alcohol or substance abuse or dependence, or illicit drug use (excluding marijuana use). - Any illness or condition that in the opinion of the investigator may affect the safety of the participant or the evaluation of any study endpoint.

Trial Details

Identifiers

Identifier Owner
NCT04642638 ClinicalTrials.gov: US National Institutes of Health
COVID19-311 -

Organisations

  • Sponsors Inovio Pharmaceuticals
  • Affiliations Inovio Pharmaceuticals

Trial Dates

  • Initiation Dates

    Planned : 01 Nov 2020

    Actual : 30 Nov 2020

  • Primary Completion Dates

    Planned : 01 Sep 2022

  • End Dates

    Planned : 01 Sep 2022

Other Details

  • Design double-blind; multicentre; prospective; randomised; sequential
  • Phase of Trial Phase II/III
  • Location Asia; Latin America; USA
  • Focus Pharmacodynamics; Therapeutic Use

Interventions

Drugs Route Formulation
INO 4800Primary Drug Intradermal Injection

Phase 2: INO-4800 Dose Group 1

Participants will receive one intradermal (ID) injection of 1.0 milligram (mg) of INO-4800 followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
Drug: INO-4800 (INO-4800 will be administered ID on Day 0 and Day 28.)
Device: CELLECTRA® 2000 (EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0 and Day 28.)

Phase 2: INO-4800 Dose Group 2

Participants will receive two ID injections of 1.0 mg (total 2.0 mg per dosing visit) of INO-4800 followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
Drug: INO-4800 (INO-4800 will be administered ID on Day 0 and Day 28.)
Device: CELLECTRA® 2000 (EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0 and Day 28.)

Phase 3: INO-4800 Optimum Dose Group

Participants will receive either one or two 1.0 mg ID injections of INO-4800 based on results from Phase 2 segment, followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
Drug: INO-4800 (INO-4800 will be administered ID on Day 0 and Day 28.)
Device: CELLECTRA® 2000 (EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0 and Day 28.)

Phase 2: Placebo Dose Group 1

Participants will receive one ID injection of placebo followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
Drug: Placebo (Sterile saline sodium citrate (SSC) buffer (SSC-0001) will be administered ID on Day 0 and Day 28.) Other Name: SSC-0001
Device: CELLECTRA® 2000 (EP using the CELLECTRA® 2000 device will be administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.)

Phase 2: Placebo Dose Group 2

Participants will receive two ID injections of placebo followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
Drug: Placebo (Sterile saline sodium citrate (SSC) buffer (SSC-0001) will be administered ID on Day 0 and Day 28.) Other Name: SSC-0001
Device: CELLECTRA® 2000 (EP using the CELLECTRA® 2000 device will be administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.)

Phase 3: Placebo Optimum Dose Group

Participants will receive either one or two ID injections of placebo based on results from Phase 2 segment, followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
Drug: Placebo (Sterile saline sodium citrate (SSC) buffer (SSC-0001) will be administered ID on Day 0 and Day 28.) Other Name: SSC-0001
Device: CELLECTRA® 2000 (EP using the CELLECTRA® 2000 device will be administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.)

Results

Adverse events

Results from the phase II segment of a phase II/III INNOVATE trial showed that INO 4800 was safe and well-tolerated in the participants (n=400). The majority of adverse events (AEs) were grade 1 and grade 2 in severity and was not reported to increase in frequency with the second dose. The number of participants experiencing each of the most common AEs did not differ between the two dosing groups [2] .

Immunogenicity

Results from the phase II segment of a phase II/II INNOVATE trial showed that the geometric mean fold rise (GMFR) of binding and neutralizing antibody levels in patients (n=400) resulting from INO 4800 were significantly greater in the 2.0 mg dose group versus the 1.0 mg dose group. The T cell immune responses measured by the ELISpot assay were also higher in the 2.0 mg dose group compared to the 1.0 mg dose group [2] .

Publications

  1. Inovio Pharmaceuticals. INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine. Media-Rel 2021;.

    Media Release

Authors

Author Total Publications First Author Last Author
Inovio Pharmaceuticals 1 1 1

Trial Centres

Investigators

Investigator Centre Name Trial Centre Country
Inovio Call Center
(267) 440-4237
clinical.trials@inovio.com
show details
-
John Ervin AMR Kansas City USA
Mammen P. Mammen Jr, M.D., FACP, FIDSA Inovio Pharmaceuticals
-
Mark Adams AMR Lexington USA
Pablo Tebas University of Pennsylvania USA
Principal Investigator Christopher Chambers
Christopher.Chambers@jefferson.edu
show details
Thomas Jefferson University USA
Principal Investigator Melinda Hamer
usarmy.detrick.medcom-wrair.mbx.clinical-trials@mail.mil
show details
Walter Reed Army Institute of Research USA
Prinicipal Investigator Barbara Rizzardi
brizzardi@velocityclinical.com
show details
Advanced Clinical Research USA
Prinicipal Investigator Corey Anderson
Corey.Anderson@amrllc.com
show details
AMR Tempe USA
Prinicipal Investigator Donna DeSantis
Donna.DeSantis@globalaes.com
show details
Synexus Clinical Research US, Inc - Phoenix Southeast USA
Prinicipal Investigator Ernie Riffer
ernie.riffer@synexus-us.com
show details
Central Phoenix Synexus Clinical Research USA
Prinicipal Investigator Jeffrey Rosen
Jeffrey.Rosen@amrllc.com
show details
AMR South Florida USA
Prinicipal Investigator Louis Saravolatz
louis.saravolatz@ascension.org
show details
Ascension St. John Hospital USA
Prinicipal Investigator Michael Jacobs
Michael.jacobs@amrllc.com
show details
AMR, Clinical Research Consortium- Las Vegas USA
Prinicipal Investigator Olutola Adetona
oadetona@tektonresearch.com
show details
Tekton Research USA
Prinicipal Investigator Patrick Yassini
pyassini@optimalsites.net
show details
Optimal Research, LLC USA
Prinicipal Investigator Sady A. Alpizar
s.alpizar.md@crtfi.com
show details
Clinical Research Trials of Florida, Inc USA
Prinicipal Investigator Vickie Miller
drmiller@dmclinicalresearch.com
show details
DM Clinical Research USA
Program Manager Amanda Bear
PennCovidVaccine@pennmedicine.upenn.edu
show details
University of Pennsylvania USA
Program Manager Barbara Bradshaw
clinicaltrialsKC@amrllc.com
show details
AMR Kansas City USA
Program Manager Ginger Switzer
amrlexington@amrllc.com
show details
AMR Lexington USA

Centres

Centre Name Location Trial Centre Country
-
-
-
Advanced Clinical Research West Jordan, Utah USA
AMR Kansas City Kansas City, Missouri USA
AMR Lexington Lexington, Kentucky USA
AMR South Florida Coral Gables, Florida USA
AMR Tempe Tempe, Arizona USA
AMR, Clinical Research Consortium- Las Vegas Las Vegas, Nevada USA
Ascension St. John Hospital Detroit, Michigan USA
Central Phoenix Synexus Clinical Research Phoenix, Arizona USA
Clinical Research Trials of Florida, Inc Tampa, Florida USA
DM Clinical Research Tomball, Texas USA
Inovio Pharmaceuticals
-
-
Optimal Research, LLC San Diego, California USA
Synexus Clinical Research US, Inc - Phoenix Southeast Chandler, Arizona USA
Tekton Research San Antonio, Texas USA
Thomas Jefferson University Philadelphia, Pennsylvania USA
University of Pennsylvania Philadelphia, Pennsylvania USA
Walter Reed Army Institute of Research Silver Spring, Maryland USA

Trial History

Event Date Event Type Comment
08 Jun 2021 Other trial event According to an Inovio Pharmaceuticals media release, the companies will evaluate the safety and efficacy of INO-4800 in a two-dose regimen (2.0 mg), administered one month apart, in a two-to-one randomization in subjects 18 years and older across several countries, primarily in Latin America and Asia Updated 15 Jun 2021
10 May 2021 Other trial event According to an Inovio Pharmaceuticals media release, Company plans to file preliminary Phase 2 results and device data with the U.S. Food and Drug Administration (FDA). Updated 13 May 2021
10 May 2021 Results According to an Inovio Pharmaceuticals media release, result has been published as a pre-print in MedRxiv. Updated 13 May 2021
10 May 2021 Results Phase 2 results presented in the Inovio Pharmaceuticals Media Release. Updated 13 May 2021
23 Apr 2021 Other trial event According to an Inovio Pharmaceuticals media release, given the increasing availability of vaccines authorized for emergency use, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, in coordination with the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency, will discontinue funding for the Phase 3 segment of the trial, while continuing to fund the completion of phase 2 segment. Updated 30 Apr 2021
23 Feb 2021 Other trial event Last checked against ClinicalTrials.gov record. Updated 23 Feb 2021
19 Feb 2021 Status change - active, no longer recruiting Status changed from recruiting to active, no longer recruiting. Updated 23 Feb 2021
07 Dec 2020 Other trial event According to an Inovio Pharmaceuticals media release, first patient has been dosed in the trial. The company plans to fully enroll the Phase 2 segment of the trial by the end of this month. Updated 13 Dec 2020
03 Dec 2020 Other trial event New source identified and integrated: (ClinicalTrials.gov: US National Institutes of Health: NCT04642638). Updated 03 Dec 2020
01 Dec 2020 Status change - recruiting Status changed to recruiting. Updated 10 Dec 2020
16 Nov 2020 Other trial event According to an Inovio Pharmaceuticals media release, the phase 2 segment of the trial is expected to enroll approximately 400 participants, in order to confirm the dose (s) for the subsequent efficacy evaluation planned for the Phase 3 segment.The Phase 3 segment will be case-driven with the final number of enrollees to be determined by the incidence of COVID-19 during the Phase 3 segment. Updated 30 Nov 2020
16 Nov 2020 Other trial event According to an Inovio Pharmaceuticals media release, the company intends to work diligently to ensure diversity in enrollment, targeting specific populations that are working or residing in environments with high infection rates and/or areas where there is greater risk of exposure to SARS-CoV-2, for whom exposure may be relatively prolonged or for whom personal protective equipment (PPE) may be inconsistently used, especially in confined settings. Updated 30 Nov 2020
16 Nov 2020 Other trial event According to an Inovio Pharmaceuticals media release, the lead Principal Investigator for this trial is Dr. Pablo Tebas, Professor of Medicine at the Hospital of the University of Pennsylvania. Updated 30 Nov 2020
16 Nov 2020 Other trial event According to an Inovio Pharmaceuticals media release, the FDAs authorization to proceed with the phase 2 segment is based on its review of INOVIOs non-clinical data, device information and interim Phase 1 safety and immunogenicity data as well as its design and plans for the Phase 2 and Phase 3 segments of this planned clinical trial. Updated 30 Nov 2020
16 Nov 2020 Other trial event According to an Inovio Pharmaceuticals media release, the Phase 3 segment of this trial remains on partial clinical hold until INOVIO satisfactorily resolves the FDAs remaining questions related to the CELLECTRA 2000 device that will be used to deliver INO-4800 directly into the skin. The company plans to resolve the remaining device questions during the conduct of Phase 2 segment and prior to the start of the Phase 3 segment of the trial. Updated 30 Nov 2020
16 Nov 2020 Other trial event According to an Inovio Pharmaceuticals media release, this trial will be funded by the U.S. Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD (HA)) and the Defense Health Agency (DHA). Updated 30 Nov 2020
16 Nov 2020 Other trial event According to an Inovio Pharmaceuticals media release, the company has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with the Phase 2 segment of this planned Phase 2/3 clinical trial for INO-4800, its COVID-19 vaccine candidate. Updated 30 Nov 2020
09 Nov 2020 Other trial event According to an Inovio Pharmaceuticals media release, the company has responded to the United States Food & Drug Administration (FDA) to address the questions related to the partial clinical hold on INOVIO's Investigational New Drug Application (IND) for the Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800. Updated 23 Nov 2020
28 Sep 2020 Status change - suspended Status changed from planning to suspended, according to an Inovio Pharmaceuticals media release. Updated 29 Sep 2020
28 Sep 2020 Other trial event According to an Inovio Pharmaceuticals media release, this partial clinical hold is not due to the occurrence of any adverse events related to INOVIO's ongoing expanded Phase 1 study of INO-4800, the conduct of which may continue and is not impacted by the FDA's notification. In addition, this partial clinical hold does not impact the advancement of INOVIO's other product candidates in development. INOVIO and its partners are continuing to prepare for this trial, following resolution of the FDA. Updated 29 Sep 2020
28 Sep 2020 Other trial event According to an Inovio Pharmaceuticals media release, until the FDA questions have been satisfactorily addressed, this study is on partial clinical hold. The company is actively working to address the FDA's questions and plans to respond in October, after which the FDA will have up to 30 days to notify INOVIO of its decision as to whether the trial may proceed. Updated 29 Sep 2020
28 Sep 2020 Other trial event According to an Inovio Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial. Updated 29 Sep 2020
10 Aug 2020 Other trial event According to an Inovio Pharmaceuticals media release, the company plans to start this trial in September. Updated 13 Aug 2020
30 Jun 2020 Other trial event According to an Inovio Pharmaceuticals media release, the company plans to initiate this study in this summer upon regulatory concurrence. Updated 05 Jul 2020
20 May 2020 Other trial event According to an Inovio Pharmaceuticals media release, this study is anticipated to start in July/August pending regulatory approval. Updated 24 May 2020
30 Apr 2020 Other trial event According to an Inovio Pharmaceuticals media release, INOVIO plans to produce one million doses of INO-4800 by the end of 2020. Updated 08 May 2020
30 Apr 2020 Other trial event According to an Inovio Pharmaceuticals media release, INOVIO today announced that it has entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG, to support large-scale manufacturing of INOVIOs investigational DNA vaccine INO-4800, which currently is in Phase 1 clinical testing in the U.S. (NCT04336410) for COVID-19 and could potentially advance to Phase 2/3 efficacy trial (CT profile 320589) this summer. Updated 08 May 2020
08 Apr 2020 New trial record New trial record Updated 08 Apr 2020
06 Apr 2020 Other trial event According to an Inovio Pharmaceuticals media release, upon attaining initial safety and immunogenicity data from Phase 1 studies, the company plans to advance INO-4800 to Phase 2 efficacy studies as rapidly as possible. Updated 08 Apr 2020

References

  1. ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2021;.

    Available from: URL: http://clinicaltrials.gov
  2. Inovio Pharmaceuticals. INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine. Media-Rel 2021;.

    Media Release
  3. Inovio Pharmaceuticals. INOVIO Reports Third Quarter 2020 Financial Results. Media-Rel 2020;.

    Media Release
  4. Inovio Pharmaceuticals. INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800. Media-Rel 2020;.

    Media Release
  5. Inovio Pharmaceuticals. INOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June. Media-Rel 2020;.

    Media Release
  6. Inovio Pharmaceuticals. INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800. Media-Rel 2021;.

    Media Release
  7. Inovio Pharmaceuticals. INOVIO and Richter-Helm BioLogics will expand existing DNA manufacturing agreement to support large-scale manufacturing of INO-4800INO-4800 Phase 2/3 U.S. clinical trial being prepared to start this summer. Media-Rel 2020;.

    Media Release
  8. Inovio Pharmaceuticals. INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19. Media-Rel 2020;.

    Media Release
  9. Inovio Pharmaceuticals. INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800. Media-Rel 2021;.

    Media Release
  10. Inovio Pharmaceuticals. INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models. Media-Rel 2020;.

    Media Release
  11. Inovio AS. INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19. Media-Rel 2020;.

    Media Release
  12. Inovio Pharmaceuticals. INOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update. Media-Rel 2020;.

    Media Release
  13. Inovio Pharmaceuticals. INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today. Media-Rel 2020;.

    Media Release
  14. Inovio Pharmaceuticals. INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense. Media-Rel 2020;.

    Media Release
Back to top